The Worst Mistake Moderna Investors Can Make in 2023
Moderna (NASDAQ: MRNA) investors didn't need to have too much patience in the early days of the pandemic. The company brought its coronavirus vaccine candidate from drawing board to market in about nine months. Next year, though, Moderna investors may need to rely on their patience.